Journey Medical Corp (DERM) USD0.0001

Sell:$7.61Buy:$8.66Price unchangedNo change

Prices delayed by at least 15 minutes
Sell:$7.61
Buy:$8.66
Change:Price unchangedNo change
Prices delayed by at least 15 minutes
Sell:$7.61
Buy:$8.66
Change:Price unchangedNo change
Prices delayed by at least 15 minutes

Company Information

About this company

Journey Medical Corporation is a commercial-stage pharmaceutical company. The Company is focused on selling and marketing of the United States Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved FDA for sale in the United States, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox, and Luxamend. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne. Luxamend is a water-based emulsion formulated to provide moist healing environment.

Key people

Lindsay A. Rosenwald
Executive Chairman of the Board
Claude Maraoui
President, Chief Executive Officer, Director
Joseph Benesch
Chief Financial Officer, Corporate Controller
Ramsey Alloush
Chief Operating Officer, General Counsel
Neil Herskowitz
Independent Director
Michael C. Pearce
Independent Director
Justin Smith
Independent Director
Miranda Jayne Toledano
Independent Director
Click to see more

Key facts

  • Shares in issue
    27.26m
  • EPIC
    DERM
  • ISIN
    US48115J1097
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • Market cap
    $229.50m
  • Employees
    41
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.